MA51162A - Schémas posologiques et compositions et procédés associés - Google Patents

Schémas posologiques et compositions et procédés associés

Info

Publication number
MA51162A
MA51162A MA051162A MA51162A MA51162A MA 51162 A MA51162 A MA 51162A MA 051162 A MA051162 A MA 051162A MA 51162 A MA51162 A MA 51162A MA 51162 A MA51162 A MA 51162A
Authority
MA
Morocco
Prior art keywords
processes
related compositions
dosage schedules
schedules
dosage
Prior art date
Application number
MA051162A
Other languages
English (en)
Inventor
Pascal Deschatelets
Cedric Francois
Federico Grossi
Patrick Johnson
Carolina Vega
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of MA51162A publication Critical patent/MA51162A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
MA051162A 2017-12-15 2018-12-14 Schémas posologiques et compositions et procédés associés MA51162A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599637P 2017-12-15 2017-12-15
US201862655094P 2018-04-09 2018-04-09
US201862744565P 2018-10-11 2018-10-11

Publications (1)

Publication Number Publication Date
MA51162A true MA51162A (fr) 2020-10-21

Family

ID=66820978

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051162A MA51162A (fr) 2017-12-15 2018-12-14 Schémas posologiques et compositions et procédés associés

Country Status (7)

Country Link
US (4) US20200316163A1 (fr)
EP (1) EP3724211A4 (fr)
JP (3) JP2021507884A (fr)
KR (2) KR20200123091A (fr)
AU (2) AU2018386304B2 (fr)
MA (1) MA51162A (fr)
WO (1) WO2019118938A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
US11040107B2 (en) * 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2019118938A1 (fr) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Schémas posologiques et compositions et procédés associés
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020210404A1 (fr) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Formes posologiques et schémas de traitement pour des composés d'acides aminés
EP4087541A4 (fr) * 2020-01-07 2024-03-27 Apellis Pharmaceuticals, Inc. Traitement de l'hémoglobinurie paroxystique nocturne
TW202308637A (zh) * 2021-04-30 2023-03-01 美商普萊恩醫療公司 整合素抑制劑之擴大劑量方案

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5157110A (en) 1988-08-20 1992-10-20 The Government Of The United States Of America Synthetic, anti-complement protein
IL95942A0 (en) 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP0512733A2 (fr) 1991-05-03 1992-11-11 Washington University Régulateur modifié du système complémentaire
US5492135A (en) 1992-09-09 1996-02-20 Devore; Dale P. Collagen modulators for use in photoablation excimer laser keratectomy
US5482135A (en) 1993-06-29 1996-01-09 Deere & Company Combined hydraulic reservoir and vehicle axle
WO1995003009A1 (fr) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Methode de traitement de la degenerescence maculaire
WO1995003807A1 (fr) 1993-07-27 1995-02-09 The University Of Sydney Traitement de la degenerescence maculaire due au vieillissement
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH08280800A (ja) 1995-04-12 1996-10-29 Nissho Corp ２液注射用プレフィルドシリンジ
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU2203197A (en) 1996-03-13 1997-10-01 Trustees Of The University Of Pennsylvania, The Novel peptides which inhibit complement activation
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
WO1997047321A1 (fr) 1996-06-14 1997-12-18 The Johns Hopkins University School Of Medicine Utilisation de proteines chimeres regulatrices du complement du virus vaccinal pour inhiber ledit complement
JPH1087700A (ja) 1996-06-17 1998-04-07 Smithkline Beecham Corp Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU4648197A (en) 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JPH11197234A (ja) 1998-01-09 1999-07-27 Koken Co Ltd 眼科用コラーゲンゲル成形物
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US6214790B1 (en) 1998-04-10 2001-04-10 Mayo Foundation For Medical Education And Research Neo-tryptophan
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7084106B1 (en) 1999-01-19 2006-08-01 University Of Louisville Research Foundation, Inc. Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease
EP1154734B1 (fr) 1999-02-12 2014-10-01 ProChon Biotech Ltd. Systeme injectable a base de collagene pour l'administration de cellules
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
ATE303816T1 (de) 1999-05-25 2005-09-15 King Faisal Specialist Hospita Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US20050020525A1 (en) 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
WO2001084149A2 (fr) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostic et therapeutique pour des troubles lies a une degenerescence maculaire
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
WO2002011793A1 (fr) 2000-08-08 2002-02-14 Medical Information Services, Inc. Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US6534058B2 (en) 2000-10-10 2003-03-18 Tanox, Inc. Anti-C5 monoclonal antibodies
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
EP1372602B1 (fr) 2001-01-09 2007-04-18 Microchips, Inc. Dispositifs flexibles a micropuces a usage ophtalmique ou autre
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20050054596A1 (en) 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
HRP20040406A2 (en) 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
EP1453546A2 (fr) 2001-12-04 2004-09-08 Nanospectra Biosciences, Inc. Traitement d'etats pathologiques se caracterisant par une angiogenese excessive ou inappropriee
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
US20040087513A1 (en) * 2002-07-04 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations based on sodium channel blockers and magnesium salts
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP3976635B2 (ja) 2002-08-05 2007-09-19 久光製薬株式会社 キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにｘ線造影剤キット製剤
SI1549333T1 (sl) 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
US20060251621A1 (en) 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
US7459169B2 (en) 2002-10-21 2008-12-02 Allvivo, Inc. Surface coating comprising bioactive compound
AU2003301813A1 (en) 2002-10-30 2004-06-07 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
JP2006518750A (ja) 2003-02-21 2006-08-17 リクスホスピタレット−ラジウムホスピタレット・ホーエフ 胎便吸引症候群の治療のための方法および組成物
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2005023296A1 (fr) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Traitement de maladies rhumatismales
US7348401B2 (en) 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
HUE050481T2 (hu) 2004-02-12 2020-12-28 Archemix Llc Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
WO2005107708A1 (fr) 2004-04-30 2005-11-17 Allergan, Inc. Implants d'inhibiteurs de tyrosine kinase intravitreens, biodegradables
US20070142339A1 (en) 2004-05-10 2007-06-21 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1768692B8 (fr) 2004-07-01 2015-06-17 Yale University Materiaux polymères chargés de médicaments et ciblés à haute densité
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US7947267B2 (en) 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
BRPI0518289A2 (pt) 2004-11-18 2008-11-11 Univ Yale mÉtodos e composiÇÕes para o tratamento de desordens oculares
CA2597411C (fr) 2005-02-14 2014-08-12 University Of Iowa Research Foundation Utilisation des polymorphismes du facteur h du complement pour le traitement et le diagnostic de la degenerescence maculaire liee a l'age
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US20090117171A1 (en) 2005-03-11 2009-05-07 Cedric Francois Compositions and methods for treatment of macular degeneration and related conditions
EP1888629B1 (fr) 2005-05-10 2013-04-24 Neoloch Aps Peptides neuritogenes
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
BRPI0617186A2 (pt) * 2005-10-08 2011-07-19 Potentia Pharmaceuticals Inc uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste
US20070134244A1 (en) 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
HUE026423T2 (en) 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
RU2474586C2 (ru) 2005-11-28 2013-02-10 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Эффективные аналоги компстатина
AU2006330501B2 (en) 2005-12-22 2012-04-05 Alcon Research, Ltd. C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
EP1998809B1 (fr) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Conjugués de camptothecin et peptide pénétrant la cellule et composition pharmaceutique les contenant.
EP3753548A1 (fr) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Formulations antagonistes vegf appropriées pour l'administration intravitréenne
US20070293873A1 (en) 2006-06-19 2007-12-20 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
WO2008097525A2 (fr) 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Inhibition locale de complément destinée au traitement de troubles induits par le complément
AU2007356525B2 (en) 2007-07-19 2014-07-17 Allexcel, Inc. Self-assembling amphiphilic polymers as anticancer agents
WO2009015087A2 (fr) 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions et procédés de traitement d'un traumatisme
KR20100094453A (ko) 2007-10-02 2010-08-26 포텐시아 팔마큐티칼스, 인크. 겔로부터 콤스타틴 유사체의 지속적 운반
ES2612736T3 (es) 2007-11-16 2017-05-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
WO2009121065A2 (fr) 2008-03-28 2009-10-01 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
CA2760839C (fr) 2009-05-01 2019-02-12 The Trustees Of The University Of Pennsylvania Compstatine modifiee avec squelette peptidique et modifications c-terminales
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
RU2559888C2 (ru) 2009-07-10 2015-08-20 Зе Дженерал Хоспитал Корпорэйшн Аналоги этомидата, которые не ингибируют синтез адренокортикостероидов
EP2338520A1 (fr) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Conjugué doté d'un liguant de recherche de cible et son utilisation
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
WO2012040259A2 (fr) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Compstatine modifiée ayant des propriétés de stabilité et de liaison améliorées
RU2653439C9 (ru) 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PT2753636T (pt) 2011-09-07 2020-01-21 Univ Pennsylvania Análogos de compstatina com propriedades farmacocinéticas melhoradas
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014028861A1 (fr) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Détection de drusen à risque élevé
WO2014078734A2 (fr) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Analogues de la compstatine réactifs aux cellules, à longue durée d'action ou ciblés et compositions et méthodes associées
ES2780674T3 (es) * 2012-11-15 2020-08-26 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
ITMI20122263A1 (it) 2012-12-28 2014-06-29 Azienda Ospedaliero Universitaria Di Parma Nuovi peptidi cationici ciclici ad attività antimicrobica
WO2014152391A1 (fr) * 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Analogues de compstatine pénétrant dans les cellules et leurs utilisations
US9566459B2 (en) 2013-07-16 2017-02-14 Beijing Mechanical Equipment Institute Fire engine suitable for fire-fighting in high-rise and super high-rise buildings
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2015142701A1 (fr) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Analogues de compstatine de puissance et de propriétés pharmacocinétiques améliorées
WO2016172712A2 (fr) 2015-04-23 2016-10-27 Sydnexis, Inc. Composition ophtalmique
US20170246298A1 (en) 2014-09-24 2017-08-31 Apellis Pharmaceuticals, Inc. Methods and compositions for cancer treatment and treatment selection
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
CA3040917A1 (fr) 2016-10-17 2018-04-26 Apellis Pharmaceuticals, Inc. Polytherapie pour l'inhibition de c3
WO2018081521A1 (fr) * 2016-10-28 2018-05-03 Tarveda Therapeutics, Inc. Conjugués ciblant les sstr, particules et formulations de ceux-ci
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2019118938A1 (fr) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Schémas posologiques et compositions et procédés associés
WO2021007111A1 (fr) 2019-07-05 2021-01-14 Apellis Pharmaceuticals, Inc. Thérapie par vecteurs viraux

Also Published As

Publication number Publication date
US20250170209A1 (en) 2025-05-29
EP3724211A1 (fr) 2020-10-21
JP2024028797A (ja) 2024-03-05
WO2019118938A1 (fr) 2019-06-20
AU2018386304B2 (en) 2023-12-07
AU2024201445A1 (en) 2024-03-28
KR20200123091A (ko) 2020-10-28
US20250170210A1 (en) 2025-05-29
AU2018386304A1 (en) 2020-07-09
EP3724211A4 (fr) 2021-10-27
US12290566B2 (en) 2025-05-06
JP2026048076A (ja) 2026-03-16
US20200316163A1 (en) 2020-10-08
US20240115655A1 (en) 2024-04-11
US12458695B2 (en) 2025-11-04
KR20240167712A (ko) 2024-11-27
JP2021507884A (ja) 2021-02-25

Similar Documents

Publication Publication Date Title
EP3823673A4 (fr) Compositions anti-cd112r et procédés
MA45779A (fr) Polypeptides immunomdulateurs et compositions et procédés associés
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
EP3606465A4 (fr) Schémas posologiques et compositions et procédés associés
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
EP3706784A4 (fr) Compositions et procédés de production de lymphocytes t
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
PL3607069T3 (pl) Produkty i kompozycje
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
MA51162A (fr) Schémas posologiques et compositions et procédés associés
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
EP3474820C0 (fr) Compositions glp-1 et ses utilisations
EP3503879A4 (fr) Compositions et procédés associés
EP3565397A4 (fr) Compositions microbiennes et procédés
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
EP3595594A4 (fr) Stents transluminaux et procédés associés
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
EP3599868C0 (fr) Mélange herbicide, composition et procédé
MA50175A (fr) Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
EP3565396A4 (fr) Compositions microbiennes et procédés associés
PL3352766T3 (pl) Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
EP3310376A4 (fr) Agents thérapeutiques modifiés et compositions associées
EP3355881A4 (fr) Compositions orales de taxane et procédés associés